Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, filed a Form 4 on August 19, 2026, reporting the acquisition of two new restricted stock unit grants with an earliest transaction date of August 17, 2026, and disclosing her full holdings of derivative securities in the company (NASDAQ:TECH).

Key Highlights

  • New RSU grant (57,590 units): Kelderman acquired 57,590 restricted stock units on 08/17/2026 at a price of $0, with vesting of 19,197 units on each of 8/17/2027 and 8/17/2028, and 19,196 units on 8/17/2029.
  • New RSU grant (93,582 units): A second grant of 93,582 restricted stock units was also acquired on 08/17/2026 at a price of $0, vesting in full on 8/17/2029.
  • Common stock ownership: Following the reported transactions, Kelderman directly beneficially owns 82,762 shares of common stock.
  • Stock options outstanding: The filing reports ten tranches of stock options held directly, covering 452,866 underlying shares in total, with exercise prices ranging from $52.83 to $120.46.
  • Performance RSUs: Kelderman holds 51,261 performance restricted stock units subject to performance goals vesting on or around 8/15/2027, and 70,708 subject to performance goals vesting on or around 8/15/2028.
  • All reported holdings are direct: Every security reported in Table I and Table II is listed as directly owned by the reporting person.

Kelderman's RSU Awards and Full Derivative Holdings at BIO-TECHNE

According to the filing, Kim Kelderman, who serves as both Chief Executive Officer and Director of BIO-TECHNE Corp, reported two restricted stock unit acquisitions dated August 17, 2026. The first grant covers 57,590 units, each representing a contingent right to receive one share of Bio-Techne common stock, vesting in three roughly equal installments on 8/17/2027, 8/17/2028, and 8/17/2029. The second grant covers 93,582 units, all vesting on 8/17/2029. Both grants were reported at a price of $0.

The filing also discloses Kelderman's existing portfolio of derivative securities. Ten separate stock option tranches are reported, with exercise prices of $52.83, $66.97, $68.54 (two tranches), $74.91, $84.61 (two tranches), $94.52, $120.46, and $53.60, and expiration dates ranging from 08/05/2027 to 08/15/2035. Several tranches are described as fully exercisable, while others follow multi-year vesting schedules detailed in the filing's explanatory footnotes. In addition to the two new RSU grants, Kelderman holds prior restricted stock unit awards of 8,544 units vesting on 8/15/2027, and 23,569 units vesting across 8/15/2027 and 8/15/2028.

Two performance restricted stock unit awards are also reported: 51,261 units that vest in full or in part on 8/15/2027 if certain performance goals are achieved, and 70,708 units subject to the same performance conditions with a vesting date of 8/15/2028, in each case subject to certification by the Administrator. Table I reports 82,762 shares of common stock directly held following the reported transactions. The form was signed by Andrew Nick as Attorney-in-Fact for Kim Kelderman pursuant to a previously filed power of attorney.

What Was Disclosed

The filing reports two new restricted stock unit grants totaling 151,172 units acquired by BIO-TECHNE's CEO on 08/17/2026, along with a comprehensive disclosure of her existing stock options, performance RSUs, time-based RSUs, and direct common stock holdings.